Pharmaceutical opinion : **Interaction between potent inducers and anti-HCV**

Patient : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ DOB \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

After analyzing your patient's file, I noticed a problem with his medication.

**Ledipasvir / Sofosbuvir (Harvoni)**   **and**

**Anticonvulsivants**

* Carbamazepine (Tegretol)
* Oxcarbazepine (Trileptal)
* Phenobarbital (Luminal)
* Phenytoin (Dilantin)

**Interaction mecanism :** Carbamazepine, oxcarbazepine, phenobarbital and phenytoin are potent CYP 3A4 and P-gp inducers. However, according to the monographs, concomitant use of these anti-HCV drugs with potent CYP 3A4 inducers such as carbamazepine, oxcarbazepine, phenobarbital and phenytoin is contraindicated or not recommended.

***Anti-HCV and anticonvulsivants***

Additional information:

The combination of these drugs has not been studied. According to product monograph, concomitant use with potent CYP 3A4 inducers as carbamazepine, oxcarbazepine, phenobarbital and phenytoin is not recommended.

Possible therapeutic options: **Anticonvulsivant name** : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

* Substitute anticonvulsant for: gabapentin, pregabalin or levetiracetam

Dosage : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

* Other :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ REN : \_\_\_\_\_\_\_

**Follow-up :** Efficacy of anti-HCV and effectiveness and safety of the chosen alternative drug.

Do not hesitate to contact us for additional information.  
In collaboration,

Pharmacist : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Telephone : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_​ Fax : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

As a prescription, date and sign:

Date : \_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_ Signature and licence : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_